Source:http://linkedlifedata.com/resource/pubmed/id/15500427
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2004-10-25
|
| pubmed:abstractText |
Manidipine is a third-generation dihydropyridine calcium antagonist, which causes systemic vasodilation by inhibiting the voltage-dependent calcium inward currents in smooth muscle cells. In clinical studies, manidipine has been shown to significantly lower office and 24-h blood pressure compared with placebo in patients with essential hypertension. The resulting reduction in blood pressure is maintained over 24 h, with preservation of the circadian blood pressure pattern; its blood pressure-lowering capacity appears to be similar to that of other calcium antagonists. In elderly patients with mild-to-moderate essential hypertension, manidipine is able to significantly decrease blood pressure compared with placebo for up to 3 years of treatment. The drug also significantly lowers blood pressure in patients with hypertension and concomitant Type 2 diabetes mellitus or renal impairment, and is devoid of adverse metabolic effects. It is well-tolerated with few untoward adverse effects related to vasodilation. In particular, manidipine appears to have less potential for pedal edema than other calcium channel blockers.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1477-9072
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
815-27
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15500427-Adult,
pubmed-meshheading:15500427-Aged,
pubmed-meshheading:15500427-Animals,
pubmed-meshheading:15500427-Biological Availability,
pubmed-meshheading:15500427-Blood Pressure Monitoring, Ambulatory,
pubmed-meshheading:15500427-Dihydropyridines,
pubmed-meshheading:15500427-Disease Models, Animal,
pubmed-meshheading:15500427-Dose-Response Relationship, Drug,
pubmed-meshheading:15500427-Drug Administration Schedule,
pubmed-meshheading:15500427-Female,
pubmed-meshheading:15500427-Follow-Up Studies,
pubmed-meshheading:15500427-Humans,
pubmed-meshheading:15500427-Hypertension,
pubmed-meshheading:15500427-Male,
pubmed-meshheading:15500427-Maximum Tolerated Dose,
pubmed-meshheading:15500427-Middle Aged,
pubmed-meshheading:15500427-Randomized Controlled Trials as Topic,
pubmed-meshheading:15500427-Risk Assessment,
pubmed-meshheading:15500427-Severity of Illness Index,
pubmed-meshheading:15500427-Treatment Outcome
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Role of manidipine in the management of patients with hypertension.
|
| pubmed:affiliation |
University of Padova, Department of Clinical and Experimental Medicine, Via Giustiniani No. 2, I-35128 Padova, Italy. valerie.tikhonoff@unipd.it.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|